Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombolytic therapy]

T Matsuda1

  • 1Kanazawa University School of Medicine, Department of Internal Medicine (III).

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 31, 1998
PubMed
Summary
This summary is machine-generated.

Thrombolytic therapy for acute coronary syndrome is underutilized in Japan. While less effective than interventions, it offers potential prognostic benefits in early myocardial infarction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tachyphylaxis to capsaicin-induced cough and its reversal by indomethacin, in patients with the sinobronchial syndrome.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·1992
Same author

Locally invasive pulmonary aspergillosis in a healthy man successfully treated with oral fluconazole.

Internal medicine (Tokyo, Japan)·1992
Same author

Abnormal distribution of IL-6 receptor in aged MRL/lpr mice: elevated expression on B cells and absence on CD4+ cells.

International immunology·1992
Same author

Enterovesical fistula caused by inflammatory bowel diseases.

Nihon Ika Daigaku zasshi·1992
Same author

Lactate in rat skeletal muscle after hemorrhage measured by microdialysis probe calibrated in situ.

The American journal of physiology·1992
Same author

Peptidyl antithrombogenic agents for extracorporeal blood circulation.

The International journal of artificial organs·1992
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Thrombolytic therapy is less common than percutaneous coronary intervention (PCI) or stenting for acute coronary syndrome (ACS) in Japan.
  • Limitations include incomplete restoration of coronary artery patency and frequent need for subsequent interventions.

Purpose of the Study:

  • To discuss the concepts and effects of thrombolytic therapy in acute myocardial infarction.
  • To review the characteristics of newly developed thrombolytic drugs.

Main Methods:

  • Literature review and discussion of existing data on thrombolytic therapy.
  • Analysis of the role of thrombolytic agents in the peracute stage of myocardial infarction.

Main Results:

  • Thrombolytic therapy, though limited, can be administered early in myocardial infarction.

Related Experiment Videos

  • Potential for improved patient prognosis exists with timely thrombolytic administration.

    • Conclusions:

    • Despite limitations, thrombolytic therapy remains a viable option for early myocardial infarction.
    • Newer thrombolytic drugs may offer improved efficacy and characteristics.